340 related articles for article (PubMed ID: 33475177)
1. Direct targeting of β-catenin in the Wnt signaling pathway: Current progress and perspectives.
Wang Z; Li Z; Ji H
Med Res Rev; 2021 Jul; 41(4):2109-2129. PubMed ID: 33475177
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors.
Zhang H; Bao Y; Liu C; Li J; Zhu D; Zhang Q
Future Med Chem; 2021 May; 13(10):927-940. PubMed ID: 33849283
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Wang Z; Zhang M; Luo W; Zhang Y; Ji H
J Med Chem; 2021 May; 64(9):5886-5904. PubMed ID: 33902288
[TBL] [Abstract][Full Text] [Related]
4. Discovery of small molecule inhibitors of the Wnt/β-catenin signaling pathway by targeting β-catenin/Tcf4 interactions.
Yan M; Li G; An J
Exp Biol Med (Maywood); 2017 Jun; 242(11):1185-1197. PubMed ID: 28474989
[TBL] [Abstract][Full Text] [Related]
5. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.
Takada K; Zhu D; Bird GH; Sukhdeo K; Zhao JJ; Mani M; Lemieux M; Carrasco DE; Ryan J; Horst D; Fulciniti M; Munshi NC; Xu W; Kung AL; Shivdasani RA; Walensky LD; Carrasco DR
Sci Transl Med; 2012 Aug; 4(148):148ra117. PubMed ID: 22914623
[TBL] [Abstract][Full Text] [Related]
6. SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction.
Fan R; He H; Yao W; Zhu Y; Zhou X; Gui M; Lu J; Xi H; Deng Z; Fan M
DNA Cell Biol; 2018 Feb; 37(2):126-132. PubMed ID: 29271667
[TBL] [Abstract][Full Text] [Related]
7. Targeting the interaction of β-catenin and TCF/LEF transcription factors to inhibit oncogenic Wnt signaling.
Koelman EMR; Yeste-Vázquez A; Grossmann TN
Bioorg Med Chem; 2022 Sep; 70():116920. PubMed ID: 35841828
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Selective Small-Molecule Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety.
Catrow JL; Zhang Y; Zhang M; Ji H
J Med Chem; 2015 Jun; 58(11):4678-92. PubMed ID: 25985283
[TBL] [Abstract][Full Text] [Related]
9. Discovery of chemical probes that suppress Wnt/β-catenin signaling through high-throughput screening.
Yamaguchi K; Nagatoishi S; Tsumoto K; Furukawa Y
Cancer Sci; 2020 Mar; 111(3):783-794. PubMed ID: 31912579
[TBL] [Abstract][Full Text] [Related]
10. LATS2 suppresses oncogenic Wnt signaling by disrupting β-catenin/BCL9 interaction.
Li J; Chen X; Ding X; Cheng Y; Zhao B; Lai ZC; Al Hezaimi K; Hakem R; Guan KL; Wang CY
Cell Rep; 2013 Dec; 5(6):1650-63. PubMed ID: 24360964
[TBL] [Abstract][Full Text] [Related]
11. Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners.
Zhang H; Liu C; Zhu D; Zhang Q; Li J
J Med Chem; 2023 Jan; 66(1):1-31. PubMed ID: 36583662
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 1-Benzoyl 4-Phenoxypiperidines as Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Li Z; Zhang M; Teuscher KB; Ji H
J Med Chem; 2021 Aug; 64(15):11195-11218. PubMed ID: 34270257
[TBL] [Abstract][Full Text] [Related]
13. Recent advances of β-catenin small molecule inhibitors for cancer therapy: Current development and future perspectives.
Yang P; Zhu Y; Zheng Q; Meng S; Wu Y; Shuai W; Sun Q; Wang G
Eur J Med Chem; 2022 Dec; 243():114789. PubMed ID: 36183504
[TBL] [Abstract][Full Text] [Related]
14. Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer.
Liu Z; Wang P; Wold EA; Song Q; Zhao C; Wang C; Zhou J
J Med Chem; 2021 Apr; 64(8):4257-4288. PubMed ID: 33822624
[TBL] [Abstract][Full Text] [Related]
15. Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Wang Z; Zhang M; Quereda V; Frydman SM; Ming Q; Luca VC; Duckett DR; Ji H
J Med Chem; 2021 Aug; 64(16):12109-12131. PubMed ID: 34382808
[TBL] [Abstract][Full Text] [Related]
16. C644-0303, a small-molecule inhibitor of the Wnt/β-catenin pathway, suppresses colorectal cancer growth.
Yan Y; Zhang Y; Li M; Zhang Y; Zhang X; Zhang X; Xu Y; Wei W; Wang J; Xu X; Song Q; Zhao C
Cancer Sci; 2021 Nov; 112(11):4722-4735. PubMed ID: 34431598
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin.
Grossmann TN; Yeh JT; Bowman BR; Chu Q; Moellering RE; Verdine GL
Proc Natl Acad Sci U S A; 2012 Oct; 109(44):17942-7. PubMed ID: 23071338
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Optimization of Small-Molecule Inhibitors for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Zhang M; Wang Z; Zhang Y; Guo W; Ji H
J Med Chem; 2018 Apr; 61(7):2989-3007. PubMed ID: 29566337
[TBL] [Abstract][Full Text] [Related]
19. LncRNA NCK1-AS1 exerts oncogenic property in gastric cancer by targeting the miR-22-3p/BCL9 axis to activate the Wnt/β-catenin signaling.
Guan B; Ma J; Yang Z; Yu F; Yao J
Environ Toxicol; 2021 Aug; 36(8):1640-1653. PubMed ID: 33974352
[TBL] [Abstract][Full Text] [Related]
20. Drug discovery efforts toward inhibitors of canonical Wnt/β-catenin signaling pathway in the treatment of cancer: A composition-of-matter review (2010-2020).
Morris A; Pagare PP; Li J; Zhang Y
Drug Discov Today; 2022 Apr; 27(4):1115-1127. PubMed ID: 34800684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
